Stock Watch: Academia’s Undiscovered Drug Developments
Declining Pharmaceutical R&D Productivity Is A Legacy To Be Proud Of
Executive Summary
It is easy for university researchers to criticize the pharmaceutical sector’s R&D productivity when they ignore the contributions of all the drugs that have been approved, and all those that have been rejected.
You may also be interested in...
Stock Watch: Rare Diseases Beget Rare Profitability
Do rare disease drugs with tiny patient populations lie outside the profitability continuum that runs from small-molecule primary care products to specialist biologics?
Stock Watch: Cancer Combination Therapies Face Rising Bar
Improving efficacy by combining drugs has been a mainstay of cancer therapy but adding new targeted drugs together based on very early-stage data is not working out, especially when one of the drugs is barely active on its own.
Stock Watch: Biotech’s Commercial Laggards Drag On Sector
Some commercial-stage biotechnology companies blame the pandemic for their declining sales and continued losses. While an acquisition by a bigger company might once have been an aspiration, further fundraisings seem to be the more likely outcome.